Literature DB >> 18688593

[Treatment of advanced penile cancer. Do we need new methods for chemotherapy?].

C Protzel1, H-J Klebingat, O W Hakenberg.   

Abstract

Penile cancer is a squamous epithelial neoplasia with a very high mortality in advanced stages. Only few series with small patient numbers have addressed the systemic treatment of advanced penile carcinoma. Established regimens are characterized by high toxicity and poor efficacy. Due to the relative paucity of data, recommendations and guidelines on the treatment of metastatic penile carcinoma are vague. New approaches and large-scale studies that will allow better definition of adequate and more effective treatment options are needed. Encouraging results with newer chemotherapeutic agents are at present mainly anecdotal but are still encouraging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688593     DOI: 10.1007/s00120-008-1841-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  15 in total

Review 1.  Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.

Authors:  David Murdoch
Journal:  Curr Opin Oncol       Date:  2007-05       Impact factor: 3.645

2.  Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis.

Authors:  G Pizzocaro; L Piva
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

3.  Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study.

Authors:  G P Haas; B A Blumenstein; R G Gagliano; C A Russell; S E Rivkin; D J Culkin; M Wolf; E D Crawford
Journal:  J Urol       Date:  1999-06       Impact factor: 7.450

4.  Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma.

Authors:  Carlos Bermejo; J Erik Busby; Philippe E Spiess; Lior Heller; Lance C Pagliaro; Curtis A Pettaway
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

5.  Penile cancer chemotherapy: twelve years' experience at Institut Gustave-Roussy.

Authors:  J Kattan; S Culine; J P Droz; E Fadel; B Court; J L Perrin; P Wibault; C Haie-Meder
Journal:  Urology       Date:  1993-11       Impact factor: 2.649

6.  Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas.

Authors:  A M Hussein; P Benedetto; K S Sridhar
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

7.  Cisplatin and 5-fluorouracil in advanced cancer of the penis.

Authors:  F V Shammas; S Ous; S D Fossa
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

8.  Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin.

Authors:  D A Corral; A Sella; C A Pettaway; R J Amato; D M Jones; J Ellerhorst
Journal:  J Urol       Date:  1998-11       Impact factor: 7.450

9.  A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

Authors:  C Theodore; I Skoneczna; I Bodrogi; M Leahy; J M Kerst; L Collette; K Ven; S Marréaud; R D T Oliver
Journal:  Ann Oncol       Date:  2008-04-15       Impact factor: 32.976

10.  EAU Guidelines on Penile Cancer.

Authors:  E Solsona; F Algaba; S Horenblas; G Pizzocaro; T Windahl
Journal:  Eur Urol       Date:  2004-07       Impact factor: 20.096

View more
  1 in total

1.  [The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics].

Authors:  C Protzel; S Ruppin; S Milerski; K-J Klebingat; O W Hakenberg
Journal:  Urologe A       Date:  2009-12       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.